News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Maxwell Biotech Venture Fund Invests in Pivotal Clinical Trial of Oxagen Limited’s Drug Candidate for Asthma Treatment



10/4/2012 10:26:12 AM

MOSCOW--(BUSINESS WIRE)--Maxwell Biotech Venture Fund (MBVF), founded with the help of Russian government-backed RVC, announced today that its investment committee approved the terms and the amount of an investment in Eleventa, a Russian biotech company, which was founded earlier in 2012 to develop and commercialize innovative products for the treatment of asthma and other allergic respiratory diseases.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES